Clinical Supply

The clinical supply chain is unique to itself, distributing to hundreds of study sites, often world-wide. The rapid growth of biological based pharmaceuticals is apparent in clinical trials today, creating even greater demands on clinical logistics practitioners handling biological specimens such as DNA and RNA. Cold Chain IQ provides industry insights exploring how the efficient supply of clinical materials and IMPs is the lynchpin to ensuring patients are dosed on time and clinical trials run efficiently.

Contributor: George Clinical Representative
Posted: 02/23/2016
Georger

A key step in developing a new drug is the transition from the laboratory to the human subject in a Phase I clinical trial, where the new compound is given to humans for the first time. A Phase I trial is the gateway between scientific research and clinical medicine. Generally, in-human Phase I studies are conducted in healthy male patients or he Full Article »
Posted: 05/16/2016
Cold Chain Logo
Pharma IQ spoke to Ayelet Weissbach of Opko Biologics at Clinical Trial Supply Europe on the industry's biggest challenges and the hurdles experienced with blinded clinical studies. Full Video »
Contributor: Shawn Siegel
Posted: 05/01/2013
cc_podcasts
Mary Foster is the chair of the USP's committee on Packaging, Storage and Distribution. In this podcast, she discusses the regulatory challenges of transporting and distributing clinical trial materials and biologics, and also her position with Athena Pharma Solutions. Have Your SayRate this feature and give us your feedback in the comments Full Podcast »
Contributor: Gary Hutchinson
Posted: 06/29/2016
Gary Hutchinson
Clinical trial material (CTM) or investigational medicinal products (IMP) are an important part of the early stages of the life science supply chain. As trials are being run on a global scale, in markets with less than ideal infrastructure, there is a dire need for companies to work with specialized cold chain experts to engineer and design innovative distribution processes. Cold chain failure may lead to: the patient being administered an unsafe product; liability based on compliance infractions; inconsistent data results; or an entire shipment’s product integrity could be rejected by the quality department, resulting in costly delays. Full Column »
Posted: 12/22/2015
Top Content For 2015
Cold Chain IQ and Pharma IQ present the top content pieces for 2015 in this annual bumper, so you can browse through some of this year’s best articles to feature on the portals. Full Whitepaper »